Spyre Therapeutics, Inc. SYRE Other accrued liabilities
Other accrued liabilities at other companies
Other financials
Where this comes from
Reported directly by Spyre Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:OtherAccruedLiabilitiesCurrent.
The official record: Spyre Therapeutics, Inc.’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Spyre Therapeutics, Inc.'s other accrued liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Spyre Therapeutics, Inc.'s other accrued liabilities?
- Spyre Therapeutics, Inc. (SYRE) reported other accrued liabilities of $165K in Q1 2026.
- How has Spyre Therapeutics, Inc.'s other accrued liabilities changed year-over-year?
- Spyre Therapeutics, Inc.'s other accrued liabilities decreased by 55.5% year-over-year, from $371K to $165K.
- What is the long-term trend for Spyre Therapeutics, Inc.'s other accrued liabilities?
- Over 3 years (2022 to 2025), Spyre Therapeutics, Inc.'s other accrued liabilities has grown at a -18.4% compound annual growth rate (CAGR), from $330K to $179K.